Momentum Stock Watch: Pdl Biopharma Inc (PDLI)

Company Profile:

PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Recent News:

For the first quarter of 2020, the company reported total revenues were $6.0 million, consisting primarily of LENSAR product revenue. LENSAR revenues were $6.0 million, a decrease of 11% over the prior-year period, with procedure volume declining 6%.

For the fourth quarter of 2019, the company reported total revenues were negative $5.8 million, including $21.0 million in product revenue and negative $26.8 million in revenue from royalty rights – change in fair value.


Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



PDLI’s strengths can be seen in its strong efficiency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, MACD is trying to cross back up and the RSI stands at 54.43 with positive bias. We rate Pdl Biopharma Inc (PDLI) a STRONG BUY.

About the Author

has written 13189 stories on this site.

Copyright © 2012 Nine Stocks